Form 8-K

8-K — CytoDyn Inc.

Accession: 0001175680-26-000002

Filed: 2026-04-30

Period: 2026-04-30

CIK: 0001175680

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ck0001175680-20260430.htm (Primary)

EX-99.1 (ck0001175680-ex99_1.htm)

GRAPHIC (ck0001175680-ex99_1s1.jpg)

GRAPHIC (ck0001175680-ex99_1s2.jpg)

GRAPHIC (ck0001175680-ex99_1s3.jpg)

GRAPHIC (ck0001175680-ex99_1s4.jpg)

GRAPHIC (ck0001175680-ex99_1s5.jpg)

GRAPHIC (ck0001175680-ex99_1s6.jpg)

GRAPHIC (ck0001175680-ex99_1s7.jpg)

GRAPHIC (ck0001175680-ex99_1s8.jpg)

GRAPHIC (ck0001175680-ex99_1s9.jpg)

GRAPHIC (ck0001175680-ex99_1s10.jpg)

GRAPHIC (ck0001175680-ex99_1s11.jpg)

GRAPHIC (ck0001175680-ex99_1s12.jpg)

GRAPHIC (ck0001175680-ex99_1s13.jpg)

GRAPHIC (ck0001175680-ex99_1s14.jpg)

GRAPHIC (ck0001175680-ex99_1s15.jpg)

GRAPHIC (ck0001175680-ex99_1s16.jpg)

GRAPHIC (ck0001175680-ex99_1s17.jpg)

GRAPHIC (ck0001175680-ex99_1s18.jpg)

GRAPHIC (ck0001175680-ex99_1s19.jpg)

GRAPHIC (ck0001175680-ex99_1s20.jpg)

GRAPHIC (ck0001175680-ex99_1s21.jpg)

GRAPHIC (ck0001175680-ex99_1s22.jpg)

GRAPHIC (ck0001175680-ex99_1s23.jpg)

GRAPHIC (ck0001175680-ex99_1s24.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ck0001175680-20260430.htm · Sequence: 1

8-K

0001175680falseNONE00011756802026-04-302026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

CytoDyn, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

000-49908

83-1887078

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

1111 MAIN STREET, SUITE 660

VANCOUVER, Washington

98660

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 360 980-8524

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

None

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 30, 2026, at 1:00 p.m. (Pacific Time), CytoDyn Inc. (the “Company”) intends to hold an investor call and webcast to provide a corporate and clinical update. Instructions on how to access the investor call were included in a press release dated April 23, 2026, available on the Company’s website under Newsroom. Additional presentation materials relating to such call are furnished as Exhibit 99.l and are incorporated herein by reference. The presentation materials will also be posted on the Company’s website under Investor Update Calls. All information in the presentation materials speaks as of the date thereof and the Company does not assume any obligation to update said information in the future except as may be required by law.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities of that section, and the information shall not be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Presentation Slides dated April 30, 2026 (furnished with this Form 8-K).

104

Cover Page Interactive Data File

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTODYN INC.

Date:

April 30, 2026

By:

/s/ Tyler Blok

Tyler Blok

Chief Legal Officer

EX-99.1

Filename: ck0001175680-ex99_1.htm · Sequence: 2

Leronlimab – A Novel Therapeutic in CCR5+ Immuno-Oncology CYTODYN.COM / OTCMKTS: CYDY

FORWARD LOOKING STATEMENT This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements may include statements about leronlimab, its ability to provide positive health outcomes, the Company's ability to develop a successful operating strategy and thereby create shareholder value, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the regulatory determinations of leronlimab’s safety and effectiveness to treat the diseases and conditions for which we are studying the product by the U.S. Food and Drug Administration (FDA) and various drug regulatory agencies in other countries; (ii) the Company’s ability to raise additional capital to fund its operations; (iii) the Company’s ability to meet its debt and other payment obligations; (iv) the Company’s ability to retain other key employees; (v) the Company’s ability to enter into partnership or licensing arrangements with third-parties; (vi) the timely and sufficient development, through internal resources or third-party consultants, of analyses of the data generated from the Company’s clinical trials required by the FDA or other regulatory agencies in connection with applications for approval of the Company’s drug product; (vii) the Company’s ability to achieve approval of a marketable product; (viii) the design, implementation and conduct of the Company’s clinical trials; (ix) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results; (x) the market for, and marketability of, any product that is approved; (xi) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products; (xii) regulatory initiatives, compliance with governmental regulations and the regulatory approval process; (xiii) legal proceedings, investigations or inquiries affecting the Company or its products; (xiv) general economic and business conditions; (xv) changes in foreign, political, and social conditions; (xvi) stockholder actions or proposals with regard to the Company, its management, or its board of directors; and (xvii) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in subsequent Form 10-Qs and Form 8-Ks, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this presentation. Any and all projections included herein are based on management estimates only. Adverse events could negatively impact the Company’s ability to achieve such results.

Robert E. Hoffman Chief Financial Officer CFO of CytoDyn Inc. since May 2025. An industry veteran with decades of financial and leadership experience. Prior to joining CytoDyn, served as President and CEO of Kintara Therapeutics, Inc. Other prior executive roles include; Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals. Currently sits on the boards of Esperion Therapeutics, TuHURA Biosciences, and Fibrobiologics.

Jacob Lalezari, M.D. Chief Executive Officer CEO of CytoDyn Inc. since November 2023. 37 years of industry experience, including nearly 20 years of experience with leronlimab. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for such viral diseases as HIV/AIDS, CMV, HPV, HSV, Hepatitis B and C, influenza, RSV, and COVID-19, including some historical trials conducted by CytoDyn.

Development Profile – Leronlimab Novel drug candidate with data supporting multiple Mechanisms of Action (MOA) Well-tolerated with extensive safety database including more than 1,600 patients enrolled across 20+ clinical studies Large market potential across mCRC, TNBC, and other solid tumors Potential for multiple impacts in solid tumor oncology: leronlimab as a “Stand-alone” anti-cancer therapy; and leronlimab as part of a “Prime and Pair” regimen with an immune checkpoint inhibitor (“ICI”) to create a pathway to sustained remission

Colorectal Cancer (“CRC”)

CLOVER – CytoDyn’s Phase 2 Study in CRC Title CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Study (CLOVER) Design Phase 2, open-label, randomized (350 vs 700mg) 60 patient study to explore safety and efficacy of leronlimab administered with Lonsurf and Avastin in patients with third line Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC). Lead Investigator Pashtoon Kasi, M.D., M.S., Medical Director of GI Medical Oncology, City of Hope Orange County. Status / Enrollment: Target Enrollment complete Data and Safety Monitoring Board (DSMB) meetings took place in December 2025 and March 2026 Opened 700mg randomization arm No safety concerns

Conference: American Association for Cancer Research (AACR) Annual Meeting (April 2026) Poster ID: 6466 Presenter: Dr. Pashtoon Kasi Early ctDNA Readouts from City of Hope Presented at AACR (April 2026) Figure 2: ctDNA Decline by Week 2 (% decline)

Preliminary Results from CLOVER – Phase 2 mCRC Study 100% of screened patients (91/91) tested CCR5+ Well tolerated. No Grade 3 or 4 Adverse Events (AEs) or Serious Adverse Events (SAEs) related to leronlimab; no leronlimab-related dose or treatment-limiting toxicity Early ctDNA declines in first 19 patients enrolled at City of Hope (100% of patients show declines in ctDNA; median decrease of 70% at week 2) 15/22 (68%) patients with RECIST data available at Week 8 demonstrate shrinkage or classify as having stable disease Early scan results correlate with ctDNA decreases Numeric increases in PD-L1 observed in majority of patients Principal Investigator reports patients responding clinically (better with less pain)

Guest Speaker Dr. Pashtoon Kasi, M.D., M.S. Principal Investigator, CD-0-101 The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Study (“CLOVER”) Medical Director of GI Medical Oncology, City of Hope Orange County. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research. Rad Family Chair in Gastrointestinal Oncology.

Dr. Kasi (City of Hope) – early ctDNA readouts – CRC patient 103-001 1st follow-up ctDNA test After one dose of leronlimab (350mg) Baseline - Day 1, First Dose of leronlimab (350mg) On treatment: leronlimab (350mg week); and backbone of Avastin and Lonsurf 2nd follow-up ctDNA test After two doses of leronlimab (350mg) Parts Per Million (PPM): The number of tumor molecules observed per one million total molecules sequenced Patient No. 103-001 ctDNA -97% Tumor Volume -21% Stable Disease

Dr. Kasi (City of Hope) – Liver Scans – CRC Patient 103-001 Liver scans City of Hope, CLOVER Study “After” scans were taken 8 weeks post-treatment: leronlimab (350mg once/week); and backbone of Avastin and Lonsurf Patient No. 103-001 ctDNA -97% Tumor Volume -21% Stable Disease Conference: American Association for Cancer Research (AACR) Annual Meeting (April 2026) Poster ID: 6466 Presenter: Dr. Pashtoon Kasi

Dr. Kasi (City of Hope) – Lung Scan – CRC Patient 103-001 Lung scans City of Hope, CLOVER Study “After” scans were taken 8 weeks post-treatment: leronlimab (350mg once/week); and backbone of Avastin and Lonsurf Patient No. 103-001 ctDNA -97% Tumor Volume -21% Stable Disease Conference: American Association for Cancer Research (AACR) Annual Meeting (April 2026) Poster ID: 6466 Presenter: Dr. Pashtoon Kasi

Dr. Kasi (City of Hope) – Biopsy Tissue – CRC Patient 103-001 PD-L1 Staining on Biopsy Tissue City of Hope, standard of care Disclosure: The follow-up biopsy was taken at the discretion of the treating physician and this respective patient. The CLOVER study protocol only provides for a biopsy as part of the initial screening process, whether current or historical. Baseline Follow-up CPS Score* 1% CPS Score* 5% *PD-L1 CPS (Pathology) Proportion of cancer cells plus immune cells (lymphocytes and macrophages) with PD-L1 staining, relative to total number of viable cancer cells.

Phase 3 Sunlight study - published May 3, 2023 https://www.nejm.org/doi/full/10.1056/NEJMoa2214963 N = 246 patients Median Progression Free Survival (mPFS) = 5.6 months Median Overall Survival (mOS) = 10.8 months Overall Response Rate (ORR) = 6.1%, no CRs Meta-analysis of real-world data - published May 24, 2023 https://pubmed.ncbi.nlm.nih.gov/37366880/ N = 437 patients Median Progression Free Survival (mPFS) = 4.5 months Median Overall Survival (mOS) = 11.1 months Overall Response Rate (ORR) = 2.7% Historical review of Lonsurf + Avastin in 3rd Line mCRC

Clinical Plan in CRC 1) CLOVER – Phase 2 study in 3rd line or later, patients with MSS mCRC: Amendment #6: Study extension for stable patients; andRollover arm for salvage therapy for patients with documented progression (Leronlimab 700mg + ICI). 2) A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) with Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Patients with Colorectal Cancer Liver Metastases (CHAMP) – IRB# 25965 CRC patients in earlier line of treatment; Jointly funded with City of Hope; Leveraging hepatic-protective and anti-tumor effects of leronlimab; and ctDNA results from patients on leronlimab monotherapy 3) Leronlimab + ICI in patients with CRC

Triple-Negative Breast Cancer (“TNBC”)

Relative Fluorescence Units No follow up CTC samples available Clinical Outcome(s): Survival Based on PD1/PD-L1 Inhibitors Leronlimab in TNBC – *Retrospective* clinical data (N=28)

Leronlimab in TNBC – Clinical and Pre-Clinical Data Preclinical data: 98% reduction in metastasis in mice treated with leronlimab *Retrospective* clinical data: Reduction of CTCs in 16/28 (57%) of patients Significant upregulation of PD-L1 on CTCs observed in: 16/21 (76%) of patients irrespective of dose 1/4 (25%) of patients who received 350mg 15/17 (88%) of patients who received 525mg or 700 mg Clinical outcomes: 5/5 (100%) of patients who upregulated PD-L1 and received an immune checkpoint inhibitor (“ICI”), are alive after 5+ years (3/5 currently report no evidence of disease) For metastatic TNBC, the median overall survival is typically 11 to 13 months (https://pmc.ncbi.nlm.nih.gov/articles/PMC11120599/) 23/23 (100%) of patients who did not upregulate PD-L1 or did not receive an ICI, are deceased

Clinical Plan in TNBC Phase 2 study of leronlimab with standard of care in 2nd line or later, HER2- patients with breast cancer Part 1 – Dose escalation: safety, PK, ctDNA, and PD-L1 (Dr. Paula Pohlmann of MD Anderson to serve as Principal Investigator) Part 2 – Contribution of components (+/- ICI)Adaptive study design in up to 120 patients Expanded access protocol for 2nd line or later, patients with mTNBCFirst patient dosed week of April 20, 2026 Prospective confirmation of PD-L1 inductionExternally funded for 1st 20 patients Neoadjuvant leronlimab in HER2- patients with breast cancer Exploring potential benefits of leronlimab as a monotherapy

Clinical Priorities, Upcoming Milestones, Approach to Calendar 2026

Clinical Priorities Confirm stand-alone benefit of leronlimab plus backbone, through biomarker collection, Disease Control Rate (DCR), Overall Response Rate (ORR), Progression-Free Survival (PFS) and Overall Survival (OS). Prospectively demonstrate leronlimab induction of PD-L1. Prospectively demonstrate clinical benefit of adding an ICI to leronlimab in PD-L1-induced patients. Identify optimal leronlimab dosing in oncology.

Recent & Upcoming Milestones Close on Funding for Expanded Access Program [1Q Calendar 2026] Close $17.5 Million Financing to Fund Continued Development of Leronlimab [1Q Calendar 2026] Present initial ctDNA readouts from mCRC study at AACR (San Diego) [2Q Calendar 2026] TNBC Expanded Access Program enrolls first patient [2Q Calendar 2026] Submission of protocol amendment(s) to FDA regarding inclusion and timing of ICIs in current Phase 2 mCRC (CLOVER) study [2Q Calendar 2026] Initiation of City of Hope investigator-initiated study in mCRC [2Q/3Q Calendar 2026] Initiation of dose escalation study in mTNBC [3Q Calendar 2026] Presentation at ESMO (Madrid, Spain) [4Q Calendar 2026] Presentation at ASCO GI (San Francisco) [1Q Calendar 2027]

Calendar 2026 strategy – FDA and potential partnership(s) Confirm early safety and efficacy readouts; generate optimal data package(s) [3Q Calendar 2026] Presentation of updated biomarker and clinical data at ESMO [October 2026] Assemble data to support Fast-track and/or Breakthrough Therapy Designation(s) [2H Calendar 2026] Continued evaluation of strategic partnership opportunities [2H Calendar 2026]

GRAPHIC

Filename: ck0001175680-ex99_1s1.jpg · Sequence: 3

Binary file (210379 bytes)

Download ck0001175680-ex99_1s1.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s2.jpg · Sequence: 4

Binary file (727488 bytes)

Download ck0001175680-ex99_1s2.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s3.jpg · Sequence: 5

Binary file (280828 bytes)

Download ck0001175680-ex99_1s3.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s4.jpg · Sequence: 6

Binary file (312931 bytes)

Download ck0001175680-ex99_1s4.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s5.jpg · Sequence: 7

Binary file (339608 bytes)

Download ck0001175680-ex99_1s5.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s6.jpg · Sequence: 8

Binary file (182064 bytes)

Download ck0001175680-ex99_1s6.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s7.jpg · Sequence: 9

Binary file (319339 bytes)

Download ck0001175680-ex99_1s7.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s8.jpg · Sequence: 10

Binary file (306291 bytes)

Download ck0001175680-ex99_1s8.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s9.jpg · Sequence: 11

Binary file (387277 bytes)

Download ck0001175680-ex99_1s9.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s10.jpg · Sequence: 12

Binary file (277121 bytes)

Download ck0001175680-ex99_1s10.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s11.jpg · Sequence: 13

Binary file (359705 bytes)

Download ck0001175680-ex99_1s11.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s12.jpg · Sequence: 14

Binary file (395891 bytes)

Download ck0001175680-ex99_1s12.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s13.jpg · Sequence: 15

Binary file (340946 bytes)

Download ck0001175680-ex99_1s13.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s14.jpg · Sequence: 16

Binary file (465180 bytes)

Download ck0001175680-ex99_1s14.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s15.jpg · Sequence: 17

Binary file (295252 bytes)

Download ck0001175680-ex99_1s15.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s16.jpg · Sequence: 18

Binary file (333543 bytes)

Download ck0001175680-ex99_1s16.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s17.jpg · Sequence: 19

Binary file (189692 bytes)

Download ck0001175680-ex99_1s17.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s18.jpg · Sequence: 20

Binary file (366121 bytes)

Download ck0001175680-ex99_1s18.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s19.jpg · Sequence: 21

Binary file (353573 bytes)

Download ck0001175680-ex99_1s19.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s20.jpg · Sequence: 22

Binary file (354150 bytes)

Download ck0001175680-ex99_1s20.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s21.jpg · Sequence: 23

Binary file (203682 bytes)

Download ck0001175680-ex99_1s21.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s22.jpg · Sequence: 24

Binary file (294471 bytes)

Download ck0001175680-ex99_1s22.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s23.jpg · Sequence: 25

Binary file (376861 bytes)

Download ck0001175680-ex99_1s23.jpg

GRAPHIC

Filename: ck0001175680-ex99_1s24.jpg · Sequence: 26

Binary file (274175 bytes)

Download ck0001175680-ex99_1s24.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 29

v3.26.1

Document And Entity Information

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Entity Registrant Name

CytoDyn, Inc.

Entity Central Index Key

0001175680

Entity Emerging Growth Company

false

Entity File Number

000-49908

Entity Incorporation, State or Country Code

Entity Tax Identification Number

83-1887078

Entity Address, Address Line One

1111 MAIN STREET, SUITE 660

Entity Address, City or Town

VANCOUVER

Entity Address, State or Province

Entity Address, Postal Zip Code

98660

City Area Code

360

Local Phone Number

980-8524

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

None

No Trading Symbol Flag

true

Security Exchange Name

NONE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration